Abstract 125P
Background
Immunotherapy is vital for melanoma treatment, with tumor vaccines showing promise. Previous studies suggest circadian rhythms may impact immune responses, yet their effect on tumor vaccine efficacy is unclear. To optimize vaccine outcomes, we investigated the differences in melanoma treatment efficacy when vaccines were administered at different times, aiming to find the optimal therapeutic window.
Methods
We compared the efficacy of a neoantigen tumor vaccine developed by our team when administered during the active phase (ZT21) versus the rest phase (ZT9) in C57BL/6 mice with B16-F10 melanoma (ZT refers to Zeitgeber Time, where ZT0 is the time of lights on, and ZT12 is lights off). IVIS imaging was used to track vaccine targeting of lymph nodes at different time points. Flow cytometry, immunohistochemistry, and RT-PCR were performed to assess changes in CD8+ and CD4+ T cells in the tumor microenvironment, lymph nodes, and spleen post-vaccination.
Results
In a melanoma model, vaccine administration during the rest phase (ZT9) showed better tumor inhibition compared to the active phase (ZT21). IVIS results indicated faster lymph node targeting at ZT9. Flow cytometry and immunohistochemistry revealed that ZT9 administration increased tumor-infiltrating CD8+ and CD4+ T cells, with a higher proportion of CD69+ T cells, leading to stronger anti-tumor immune responses.
Conclusions
Administering tumor vaccines during the rest phase, compared to the active phase, leads to faster lymph node targeting and stronger anti-tumor immune responses, resulting in better therapeutic outcomes. Thus, treatment timing should be considered in clinical immunotherapy, with vaccines administered during the rest phase for maximum clinical benefit.
Legal entity responsible for the study
West China Hospital, Sichuan University.
Funding
Sichuan Science and Technology Program.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
31P - Peripheral-blood Immune-predictors of pathological complete response in patients with triple-negative breast cancer undergoing neoadjuvant chemo-immunotherapy
Presenter: Celeste Santoro
Session: Poster Display session
Resources:
Abstract
32P - Immune T cell subsets dynamics in the early TNBC treatment setting
Presenter: Rocío Martín Lozano
Session: Poster Display session
Resources:
Abstract
33P - Tumor-specific CD4 Th1 responses in long-term responder melanoma patients treated with immune checkpoint inhibitors.
Presenter: Jessica Mathiot
Session: Poster Display session
Resources:
Abstract
34P - Linking early immunity changes to clinical outcomes in cutaneous squamous cell carcinoma following anti-programmed death cell-1 (PD-1) treatment
Presenter: Marcella Scala
Session: Poster Display session
Resources:
Abstract
36P - Exploring the role of soluble B7-H3 (sB7-H3) as a biomarker to predict the clinical benefit and/or the occurrence of immune related adverse events (irAEs) in advanced cancer patients treated with immune checkpoint inhibitors (ICIs)
Presenter: Luigi Liguori
Session: Poster Display session
Resources:
Abstract
37P - Lymphocyte Subpopulation Balances as a Blood Biomarker for Immune-Related Adverse Events in Patients Receiving Immune Checkpoint Inhibitors
Presenter: Mireille Langouo fontsa
Session: Poster Display session
Resources:
Abstract
38P - Biomarkers predictive of response to immune checkpoint inhibitor therapy in patients with metastatic melanoma
Presenter: Eliza Bob
Session: Poster Display session
Resources:
Abstract
39P - Analysis of the immune response patterns in localized prostate cancer
Presenter: Sara Merler
Session: Poster Display session
Resources:
Abstract
40P - MANIFEST: A Multiomic Profiling Platform for Immuno-Oncology Biomarker Discovery
Presenter: Zayd Tippu
Session: Poster Display session
Resources:
Abstract
41P - Total tumor burden and radiomics to evaluate response in dose escalation studies: Roginolisib (IOA-244), a highly selective PI3Kd inhibitor in metastatic uveal melanoma patients
Presenter: Anna Di Giacomo
Session: Poster Display session
Resources:
Abstract